Levalox (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes needed for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial DNA synthesis, leading to rapid bactericidal activity against many Gram‑positive and Gram‑negative organisms.

The dosage and duration of Levalox are determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal function, and other clinical factors. Specific dosing regimens are not provided here.

Levalox falls under an unknown pregnancy category, and safety data are limited. It should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant, and after a careful risk‑benefit assessment by the healthcare provider.

To order Levalox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.

Levalox (levofloxacin) offers a broad spectrum of activity similar to other fluoroquinolones but provides enhanced gram‑negative coverage and a once‑daily dosing option when given intravenously. Compared with older agents, it may have a lower risk of certain drug‑interaction profiles, though safety considerations such as tendon toxicity and QT prolongation remain class‑related.

Levalox should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Levalox is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber according to the infection being treated and patient-specific factors.

Serious risks include tendon rupture or tendinitis, especially in the Achilles tendon, QT interval prolongation that can lead to arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, peripheral neuropathy, and anaphylaxis. Patients should be monitored closely for these events.

Levalox should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation, and patients receiving concomitant medications that strongly interact with levofloxacin unless benefits outweigh risks.